Apremilast

Abstract

Apremilast is an orally used small-molecule inhibitor of phosphodiesterase-4. It has been approved for the treatment of adult patients with psoriatic arthritis and moderate to severe plaque psoriasis. Clinical studies have reported that it is also effective in hairy skin and nail psoriasis, generalized pustular psoriasis, and palmoplantar pustulosis. In psoriasis vulgaris, a PASI75 response was achieved in 30-70% of the patients in 12-16 weeks. It is generally well-tolerated, and its most common side effects are diarrhea, headache, and nausea, all of which disappear in time.